Global Lung Cancer Therapeutics Market 2023-2027

Description

List of Tables

Technavio has been monitoring the lung cancer therapeutics market and it is poised to grow by $10204.33 mn during 2023-2027, accelerating at a CAGR of 7.92% during the forecast period. Our report on the lung cancer therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the heavy contribution of immunomodulators, the strong prevalence of lung cancer, and the increasing number of patient assistance programs.

Technavio's lung cancer therapeutics market is segmented as below:

By Therapy

Targeted therapy
Immunotherapy
Chemotherapy

By Type

NSCLC
SCLC

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the advent of regenerative therapies as one of the prime reasons driving the lung cancer therapeutics market growth during the next few years. Also, increasing strategic alliances and the advent of protein biomarkers will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the lung cancer therapeutics market covers the following areas:

Lung cancer therapeutics market sizing
Lung cancer therapeutics market forecast
Lung cancer therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lung cancer therapeutics market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Galecto Inc., GlaxoSmithKline Plc, IOVANCE Biotherapeutics Inc., Johnson and Johnson, Merck and Co. Inc., Moderna Inc., Novartis AG, Parexel International Corp., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., and Boehringer Ingelheim International GmbH. Also, the lung cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR71021

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Therapy
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global lung cancer therapeutics market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global lung cancer therapeutics market 2017 - 2021 ($ million)
4.2 Therapy Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
4.3 Type Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy

6.1 Market segments
Exhibit 30: Chart on Therapy - Market share 2022-2027 (%)
Exhibit 31: Data Table on Therapy - Market share 2022-2027 (%)
6.2 Comparison by Therapy
Exhibit 32: Chart on Comparison by Therapy
Exhibit 33: Data Table on Comparison by Therapy
6.3 Targeted therapy - Market size and forecast 2022-2027
Exhibit 34: Chart on Targeted therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Targeted therapy - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Targeted therapy - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Targeted therapy - Year-over-year growth 2022-2027 (%)
6.4 Immunotherapy - Market size and forecast 2022-2027
Exhibit 38: Chart on Immunotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Immunotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Immunotherapy - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Immunotherapy - Year-over-year growth 2022-2027 (%)
6.5 Chemotherapy - Market size and forecast 2022-2027
Exhibit 42: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by Therapy
Exhibit 46: Market opportunity by Therapy ($ million)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 47: Chart on Type - Market share 2022-2027 (%)
Exhibit 48: Data Table on Type - Market share 2022-2027 (%)
7.2 Comparison by Type
Exhibit 49: Chart on Comparison by Type
Exhibit 50: Data Table on Comparison by Type
7.3 NSCLC - Market size and forecast 2022-2027
Exhibit 51: Chart on NSCLC - Market size and forecast 2022-2027 ($ million)
Exhibit 52: Data Table on NSCLC - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Chart on NSCLC - Year-over-year growth 2022-2027 (%)
Exhibit 54: Data Table on NSCLC - Year-over-year growth 2022-2027 (%)
7.4 SCLC - Market size and forecast 2022-2027
Exhibit 55: Chart on SCLC - Market size and forecast 2022-2027 ($ million)
Exhibit 56: Data Table on SCLC - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Chart on SCLC - Year-over-year growth 2022-2027 (%)
Exhibit 58: Data Table on SCLC - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Type
Exhibit 59: Market opportunity by Type ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 61: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 62: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 63: Chart on Geographic comparison
Exhibit 64: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 73: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 74: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 75: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 76: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 UK - Market size and forecast 2022-2027
Exhibit 85: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 87: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.9 Canada - Market size and forecast 2022-2027
Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.10 China - Market size and forecast 2022-2027
Exhibit 93: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 94: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 95: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on China - Year-over-year growth 2022-2027 (%)
9.11 France - Market size and forecast 2022-2027
Exhibit 97: Chart on France - Market size and forecast 2022-2027 ($ million)
Exhibit 98: Data Table on France - Market size and forecast 2022-2027 ($ million)
Exhibit 99: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibit 100: Data Table on France - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 101: Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 102: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 103: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 104: Overview on factors of disruption
11.4 Industry risks
Exhibit 105: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 106: Vendors covered
12.2 Market positioning of vendors
Exhibit 107: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 108: AbbVie Inc. - Overview
Exhibit 109: AbbVie Inc. - Product / Service
Exhibit 110: AbbVie Inc. - Key offerings
12.4 Amgen Inc.
Exhibit 111: Amgen Inc. - Overview
Exhibit 112: Amgen Inc. - Product / Service
Exhibit 113: Amgen Inc. - Key offerings
12.5 Astellas Pharma Inc.
Exhibit 114: Astellas Pharma Inc. - Overview
Exhibit 115: Astellas Pharma Inc. - Product / Service
Exhibit 116: Astellas Pharma Inc. - Key news
Exhibit 117: Astellas Pharma Inc. - Key offerings
12.6 AstraZeneca Plc
Exhibit 118: AstraZeneca Plc - Overview
Exhibit 119: AstraZeneca Plc - Product / Service
Exhibit 120: AstraZeneca Plc - Key news
Exhibit 121: AstraZeneca Plc - Key offerings
12.7 Boehringer Ingelheim International GmbH
Exhibit 122: Boehringer Ingelheim International GmbH - Overview
Exhibit 123: Boehringer Ingelheim International GmbH - Business segments
Exhibit 124: Boehringer Ingelheim International GmbH - Key news
Exhibit 125: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 126: Boehringer Ingelheim International GmbH - Segment focus
12.8 Bristol Myers Squibb Co.
Exhibit 127: Bristol Myers Squibb Co. - Overview
Exhibit 128: Bristol Myers Squibb Co. - Product / Service
Exhibit 129: Bristol Myers Squibb Co. - Key offerings
12.9 Daiichi Sankyo Co. Ltd.
Exhibit 130: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 131: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 132: Daiichi Sankyo Co. Ltd. - Key news
Exhibit 133: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 134: Daiichi Sankyo Co. Ltd. - Segment focus
12.10 Eli Lilly and Co.
Exhibit 135: Eli Lilly and Co. - Overview
Exhibit 136: Eli Lilly and Co. - Product / Service
Exhibit 137: Eli Lilly and Co. - Key offerings
12.11 F. Hoffmann La Roche Ltd.
Exhibit 138: F. Hoffmann La Roche Ltd. - Overview
Exhibit 139: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 140: F. Hoffmann La Roche Ltd. - Key news
Exhibit 141: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 142: F. Hoffmann La Roche Ltd. - Segment focus
12.12 GlaxoSmithKline Plc
Exhibit 143: GlaxoSmithKline Plc - Overview
Exhibit 144: GlaxoSmithKline Plc - Business segments
Exhibit 145: GlaxoSmithKline Plc - Key offerings
Exhibit 146: GlaxoSmithKline Plc - Segment focus
12.13 Merck and Co. Inc.
Exhibit 147: Merck and Co. Inc. - Overview
Exhibit 148: Merck and Co. Inc. - Business segments
Exhibit 149: Merck and Co. Inc. - Key news
Exhibit 150: Merck and Co. Inc. - Key offerings
Exhibit 151: Merck and Co. Inc. - Segment focus
12.14 Novartis AG
Exhibit 152: Novartis AG - Overview
Exhibit 153: Novartis AG - Business segments
Exhibit 154: Novartis AG - Key offerings
Exhibit 155: Novartis AG - Segment focus
12.15 Pfizer Inc.
Exhibit 156: Pfizer Inc. - Overview
Exhibit 157: Pfizer Inc. - Product / Service
Exhibit 158: Pfizer Inc. - Key news
Exhibit 159: Pfizer Inc. - Key offerings
12.16 Sanofi SA
Exhibit 160: Sanofi SA - Overview
Exhibit 161: Sanofi SA - Business segments
Exhibit 162: Sanofi SA - Key news
Exhibit 163: Sanofi SA - Key offerings
Exhibit 164: Sanofi SA - Segment focus
12.17 Takeda Pharmaceutical Co. Ltd.
Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 169: Inclusions checklist
Exhibit 170: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 171: Currency conversion rates for US$
13.4 Research methodology
Exhibit 172: Research methodology
Exhibit 173: Validation techniques employed for market sizing
Exhibit 174: Information sources
13.5 List of abbreviations
Exhibit 175: List of abbreviations